Review
Oncology
Muhammad Umair Mushtaq, Moazzam Shahzad, Ezza Tariq, Qamar Iqbal, Sibgha Gull Chaudhary, Muhammad U. Zafar, Iqra Anwar, Nausheen Ahmed, Rajat Bansal, Anurag K. Singh, Sunil H. Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk
Summary: A systematic review and meta-analysis evaluated the outcomes of mismatched unrelated donor hematopoietic stem cell transplantation (MMUD-HSCT). The results showed that MMUD-HSCT had favorable treatment outcomes and an acceptable toxicity profile in patients lacking HLA-matched or haploidentical donors, thus expanding the accessibility of HSCT to underrepresented populations.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Helene Labussiere-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jurgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of CBT and single-allele-mismatched MMUD allo-HCT with PTCy in acute myeloid leukemia. The results showed that CBT was associated with higher incidence of graft failure and non-relapse mortality compared to MMUD, leading to lower leukemia-free survival, overall survival, and GVHD-free, relapse-free survival. In conclusion, MMUD allo-HCT with PTCy may be a preferred choice over CBT for patients without a fully matched donor.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Immunology
Scott M. Krummey, Alison J. Gareau
Summary: Advances in hematopoietic stem cell transplant have led to changes in donor selection approach, including the use of haploidentical donors or permissive HLA mismatches. However, this may increase the risk of donor-specific HLA antibodies, which can limit engraftment. Desensitization treatments can effectively reduce HLA antibodies and improve transplant outcomes. The consideration and management of HLA antibodies in donor selection are increasingly important in HSCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Neema P. Mayor, Tao Wang, Stephanie J. Lee, Michelle Kuxhausen, Cynthia Vierra-Green, Dominic J. Barker, Jeffrey Auletta, Vijaya R. Bhatt, Shahinaz M. Gadalla, Loren Gragert, Yoshihiro Inamoto, Gerald P. Morris, Sophie Paczesny, Ran Reshef, Olle Ringden, Bronwen E. Shaw, Peter Shaw, Stephen R. Spellman, Steven G. E. Marsh
Summary: This study found that UHR HLA matching may not increase overall survival probability, but it does reduce the risk of aGVHD and in certain subsets, transplant-related mortality. Matching at the UHR level warrants consideration when choosing between multiple 10 out of 10 HLA-matched donors.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Jessica Stokes, Megan S. Molina, Emely A. Hoffman, Richard J. Simpson, Emmanuel Katsanis
Summary: Bendamustine, a chemotherapeutic agent used to treat various cancers, has shown promising immunomodulatory effects in the context of allogeneic hematopoietic cell transplantation. It has been found to reduce graft-versus-host disease while enhancing graft-versus-leukemia effects, making it a potential candidate for improving clinical outcomes in transplant patients. Further studies are underway to explore the full range of its immunomodulatory effects and potential applications in clinical settings.
Article
Oncology
Elena Kum, Gabriele Jagelaviciute, Edward Li, Kenneth Williams, Santhosh Thyagu, Warren Fingrut
Summary: The article tells the story of a Canadian stem cell recipient who underwent transplantation from a matched unrelated donor for refractory chronic myelogenous leukemia, showcasing different perspectives and encouraging people to become donors.
Article
Medicine, General & Internal
Theresa Hahn, Junke Wang, Leah M. Preus, Ezgi Karaesmen, Abbas Rizvi, Alyssa Clay-Gilmour, Qianqian Zhu, Yiwen Wang, Li Yan, Song Liu, Daniel O. Stram, Loreall Pooler, Xin Sheng, Christopher A. Haiman, David Van den Berg, Amy Webb, Guy Brock, Stephen R. Spellman, Kenan Onel, Philip L. McCarthy, Marcelo C. Pasquini, Lara E. Sucheston-Campbell
Summary: Through genome-wide analysis, novel non-HLA genetic loci were found to be associated with 1-year survival after unrelated donor BMT.
Article
Education, Scientific Disciplines
Shukaib Arslan, Monzr M. Al Malki
Summary: This article presents a rational and stepwise approach to the use of MMUD for hematopoietic cell transplant in patients with hematologic malignancies. It also reviews novel approaches to reduce the incidence of graft-versus-host disease and improve transplant outcomes in MMUD recipients.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
(2022)
Article
Oncology
Yue Lu, Min Xiong, Rui-Juan Sun, Jian-Ping Zhang, Yan-Li Zhao, Zhi-Jie Wei, Xing-Yu Cao, Jia-Rui Zhou, De-Yan Liu, Dao-Pei Lu
Summary: In pediatric patients with acquired SAA, UCBD-HSCT showed higher incidence of GF, lower incidence and longer duration of platelet engraftment, and inferior FFS and GRFS compared to HSCT with HID or MUD.
LEUKEMIA & LYMPHOMA
(2022)
Article
Immunology
Wensheng Zhang, Yong Wang, Fushun Zhong, Xinghuan Wang, Robert Sucher, Cheng-Hung Lin, Gerald Brandacher, Mario G. G. Solari, Vijay S. S. Gorantla, Xin Xiao Zheng
Summary: In this study, using rodent vascularized composite allotransplantation (VCA) models, it was demonstrated that the presence of donor-derived hematopoietic stem cell (HSC) niches in vascularized bone components facilitates long-term hematopoietic chimerism and promotes tolerance in recipients without harsh myeloablation. The transplanted donor HSC niches also contribute to the maintenance and homeostasis of stable mixed chimerism. Additionally, evidence was provided that chimeric thymus plays a role in the tolerance induced by mixed chimerism through thymic central deletion. This study suggests the potential use of vascularized donor bone with pre-engrafted HSC niches as a safe and effective strategy to induce robust and stable mixed chimerism-mediated tolerance in vascularized composite allotransplantation or solid organ transplantation recipients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Elizabeth O. Stenger, Benjamin Watkins, Kelsey Rogowski, Kuang-Yueh Chiang, Ann Haight, Kathryn Leung, Muna Qayed, Sharmila Raghunandan, Yvonne Suessmuth, Leslie Kean, John Horan
Summary: Four doses of abatacept added to standard GVHD prophylaxis were found to be tolerable in pediatric patients with nonmalignant diseases following unrelated donor HCT, with no significant impact on immune reconstitution.
Article
Immunology
Chrysanthi Tsamadou, Daphne Engelhardt, Uwe Platzbecker, Elisa Sala, Thomas Valerius, Eva Wagner-Drouet, Gerald Wulf, Nicolaus Kroeger, Niels Murawski, Hermann Einsele, Kerstin Schaefer-Eckart, Sebastian Freitag, Jochen Casper, Martin Kaufmann, Mareike Duerholt, Bernd Hertenstein, Stefan Klein, Mark Ringhoffer, Sandra Frank, Christine Neuchel, Hubert Schrezenmeier, Joannis Mytilineos, Daniel Fuerst
Summary: Mismatches at the HLA-DRB3/4/5 loci may lead to an increased risk of severe graft-versus-host disease (GvHD) post-transplantation, particularly in otherwise fully matched transplant pairs. The study results suggest that mismatches at the HLA-DRB3/4/5 loci are associated with adverse outcomes in unrelated hematopoietic stem cell transplantation (uHSCT).
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Yue Lu, Yan-Li Zhao, Min Xiong, Rui-Juan Sun, Xing-Yu Cao, Zhi-Jie Wei, Dao-Pei Lu
Summary: A study on 32 PNH patients undergoing HID or MUD-HSCT showed no significant differences in 3-year OS and FFS between the two groups, but treatment-related mortality had a negative impact on outcomes. HID and MUD-HSCT are feasible and effective options for PNH patients with certain complications.
LEUKEMIA & LYMPHOMA
(2022)
Article
Medicine, Research & Experimental
Yiouli P. Ktena, Michael A. Koldobskiy, Michael I. Barbato, Han-Hsuan Fu, Leo Luznik, Nicolas J. Llosa, Azeb Haile, Orly R. Klein, Chen Liu, Christopher J. Gamper, Kenneth R. Cooke
Summary: DNA methyltransferase 3a (DNMT3a) plays a critical role in regulating T cell alloreactivity by controlling T cell signaling and differentiation pathways, thereby modulating T cell tolerance.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Hematology
Giancarlo Fatobene, Michi M. Shinohara, Lynn E. Onstad, Emily T. Silgard, Paul J. Martin, Filippo Milano, Mary E. Flowers
Summary: This study compared the frequency, clinical course, and response to therapy of eczematous dermatitis (EcD) between recipients of unrelated cord blood transplantation (CBT) and non-CBT recipients. The incidence of EcD was found to be higher in CBT recipients, with a more protracted course, but most cases can be successfully managed with only topical therapy, and few cases require systemic therapy.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)